These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3098043)

  • 41. Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992-98.
    Robert J; Cambau E; Grenet K; Trystram D; Péan Y; Fiévet MH; Jarlier V
    Clin Microbiol Infect; 2001 Oct; 7(10):553-61. PubMed ID: 11683796
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar.
    Hyatt JM; Nix DE; Schentag JJ
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2730-7. PubMed ID: 7695254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].
    Thabaut A; Durosoir JL
    Pathol Biol (Paris); 1982 Jun; 30(6):394-7. PubMed ID: 6810283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
    Richards RM; Hamilton VE; Thomas MR
    J Antimicrob Chemother; 1998 Aug; 42(2):171-8. PubMed ID: 9738834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone.
    Neu HC; Chin NX
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):644-50. PubMed ID: 2506029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
    Duncan IB; Skulnick M; Marshall PW
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():1-6. PubMed ID: 6438046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Jan; 49(1):34-70. PubMed ID: 8851305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [In vitro antibacterial activity of ciprofloxacin against uropathogenic organisms].
    Allocati N; Catamo G; Cellini L
    Boll Soc Ital Biol Sper; 1984 Oct; 60(10):1927-33. PubMed ID: 6440583
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
    Loza E; Cantón R; Pascual A; Tubau F; Morosini MI; Almaraz F; Perea E; Martín R; Jones RN; Baquero F
    Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the in vitro susceptibility and emergence of mutants resistant to ciprofloxacin among multidrug resistant clinical isolates.
    Lopes CA; Mendes RP; Curi PC; Watanabe DS; Decarlis RM; Horácio A; Michelin LA; Placidelli BA
    Rev Latinoam Microbiol; 1993; 35(4):345-9. PubMed ID: 8066328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae.
    Ruiz J; Gómez J; Navia MM; Ribera A; Sierra JM; Marco F; Mensa J; Vila J
    Diagn Microbiol Infect Dis; 2002 Apr; 42(4):257-61. PubMed ID: 12007443
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cross-resistance of nalidixic acid resistant Enterobacteriaceae to new quinolones and other antimicrobials.
    Piddock LJ; Diver JM; Wise R
    Eur J Clin Microbiol; 1986 Aug; 5(4):411-5. PubMed ID: 3758052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
    Cullmann W; Stieglitz M; Baars B; Opferkuch W
    Chemotherapy; 1985; 31(1):19-28. PubMed ID: 3156025
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [In-vitro activity of cefonicid on hospital bacteria. Regression line and proposal for critical values].
    Chanal M; Cluzel M; Sirot D; Joly B; Sirot J; Cluzel R
    Pathol Biol (Paris); 1986 May; 34(5):385-9. PubMed ID: 3095773
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.
    Hoogkamp-Korstanje JA
    Eur J Clin Microbiol; 1984 Aug; 3(4):333-8. PubMed ID: 6237901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Sensitivity to antibiotics of bacteria from nosocomial infections. Evolution in resuscitation services of military hospitals].
    Garrabé E; Cavallo JD; Brisou P; Chapalain JC; Coué JC; Courrier P; Granic G; Hervé V; Koeck JL; Morillon M; Claude JD; Rouby Y; Teyssou R
    Presse Med; 2000 Sep; 29(27):1497-503. PubMed ID: 11045115
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.
    Machka K; Braveny I
    Eur J Clin Microbiol; 1987 Aug; 6(4):482-5. PubMed ID: 3117538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.